Literature DB >> 18773736

Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation.

Lars Egevad1.   

Abstract

Histologic grading remains the most useful tissue-based predictor of prognosis of prostate cancer. The Gleason system is now the only grading system recommended by the World Health Organization (WHO) for prostatic carcinoma. In recent years, there has been a gradual shift of how the Gleason grading is applied in practice. There has been a general trend toward upgrading of prostate cancer. A consensus conference was organized in 2005 by the International Society of Urological Pathology with the purpose to standardize both the perception of histologic patterns and how grade information is compiled and reported. The recommendations regarding pattern interpretation are summarized and discussed in this review.

Entities:  

Mesh:

Year:  2008        PMID: 18773736

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  5 in total

1.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.

Authors:  Paul Mak; Irwin Leav; Bryan Pursell; Donggoo Bae; Xiaofang Yang; Cherie A Taglienti; Lindsey M Gouvin; Vishva M Sharma; Arthur M Mercurio
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

Review 2.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

3.  Why can't nomograms be more like Netflix?

Authors:  Andrew J Vickers; Paul Fearn; Peter T Scardino; Mike W Kattan
Journal:  Urology       Date:  2009-10-30       Impact factor: 2.649

4.  Prediction models in urology: are they any good, and how would we know anyway?

Authors:  Andrew Vickers
Journal:  Eur Urol       Date:  2009-12-29       Impact factor: 20.096

5.  Reinventing diagnostics for personalized therapy in oncology.

Authors:  Diponkar Banerjee
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.